Entries by CTIC Team

I-Mab closes one of China’s biggest-ever biotech fundraisings

China’s I-Mab Biopharma just raised a massive $220 million in a third-round fundraising that once again reveals the growing strength of the country’s emerging biotech sector. The Shanghai-based company—which grew out of the merger between Third Venture Biopharma and Tasgen Biotech last year—says it plans to plow the cash back into its pipeline of preclinical and […]

Nabriva signs licensing deal worth up to $95 million with Chinese drug company

Nabriva Therapeutics has entered into a licensing agreement valued at up to $95 million that covers the development and commercialization of its experimental antibiotic product in China. Under the terms of the agreement, Roivant Sciences of Hong Kong will make an upfront payment of $5 million to Nabriva, which is based in Dublin, Ireland, and […]

CTIC Capital Announces 2nd Annual Cross-Border China-US Healthcare Investment Summit Attracting More Than 150 Chinese Healthcare Investors

PALO ALTO, Calif., Jan. 2, 2018 /PRNewswire/ — CTIC Capital today announced that Randy, W. Schekman, Nobel laureate, the 2013 Nobel Prize in Physiology or Medicine, Professor of Molecular and Cell Biology, University of California, Berkeley, will serve as the keynote for its second annual CTIC Capital Cross-Border Healthcare Investment Summit, co-hosted by BioCentury. Convening more than 150 Chinese […]

CTIC Capital宣布将举行第二届年度跨境中美医疗投资峰会

云集150多位中国医疗投资者的第二届年度 CTIC Capital 跨境医疗投资峰会将于2018年1月7日(周日)在旧金山凯悦酒店举行。届时,2013年诺贝尔理学与医学奖得主、加州大学伯克利分校分子与细胞生物学教授兰迪-谢克曼将发表主题演讲。 加州帕洛阿尔托2018年1月4日电 /美通社/ — CTIC Capital 今天宣布,在其与 BioCentury 联合举办的第二届年度 CTIC Capital 跨境医疗投资峰会 (CTIC Capital Cross-Border Healthcare Investment Summit) 上,2013年诺贝尔理学与医学奖 (Nobel Prize in Physiology or Medicine) 得主、加州大学伯克利分校 (University of California, Berkeley) 分子与细胞生物学教授兰迪-谢克曼 (Randy, W. Schekman) 将发表主题演讲。该峰会云集150多位中国医疗投资者,将于2018年1月7日(周日)在旧金山凯悦酒店 (Hyatt Regency San Francisco) 举行。谢克曼博士的演讲题为“关于在癌症诊断与治疗中使用外来体的前景”(Prospects for Use of Exosomes in Cancer Diagnosis and Treatment)。本次峰会的网址为:http://www.cticcapital.com/2018-healthcare-investment-summit/。 CTIC Capital 创始人兼执行合伙人 Yanhong Lin 表示:“2018年 […]

Epic Sciences To Present At The 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit

SAN DIEGO, Jan. 4, 2018 /PRNewswire/ — Epic Sciences, Inc. (Epic) announces that it is one of six companies chosen to present at the second annual CTIC Capital Cross-Border China-US Healthcare Investment Summit. The summit will take place on Sunday, January 7 at the Hyatt Regency in San Francisco. “The 2018 CTIC Capital Cross-Border Healthcare Investment Summit serves as the definitive place […]

Novocure brings Optune tech to drug trial for glioblastoma

Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Celgene and Triphase changed their ongoing Phase […]

Healthcare payment analysts Cotiviti Holdings acquires RowdMap in $70M deal

Cotiviti Holdings, a health IT vendor that specializes in analyzing healthcare payments for accuracy, has slapped down $70 million for healthcare analytics business RowdMap based in Louisville. The acquisition is intended to diversify the company’s analytics tools. Doug Williams, Cotiviti CEO, noted in a news release that the need for its services has increased in line with the shift toward […]

Forget antimicrobials, Evelo just raised $50M for its pro-microbial approach

Evelo Biosciences is doing pretty well for a preclinical company in an exploratory field. The 2014 startup has already executed a merger and raised $100 million in venture financing. The latest installment, announced Tuesday, came as a $50 million Series B courtesy of its founding and principal investor, Flagship Pioneering. GV (formerly Google Ventures), Celgene, Mayo Clinic, and Alexandria Venture […]

New York Approves Guardant Health’s Liquid Biopsy Test

May 24, 2017 | staff reporter NEW YORK (GenomeWeb) – Guardant Health today announced the Guardant360 assay has been approved by New York State’s Clinical Laboratory Evaluation Program. The assay is the first liquid biopsy permitted by the program, which Guardant said is one of the most demanding lab certification programs in the country, and the […]